Biond Announces Presentation of BND-35, Anti-ILT3 Antibody at the AACR
MISGAV, Israel, Nov. 3, 2021 /PRNewswire/ -- Biond Biologics Ltd., a private, clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, announced today the closing of a $15 million, Series C financing round.
JERUSALEM (Reuters) - Israel’s Biond Biologics Ltd said on Tuesday it had forged an exclusive global licence agreement, potentially worth more than $1 billion, with French drugmaker Sanofi for the development and commercialization of its BND-22 cancer drug.